Moderate to Severe Plaque Psoriasis Pipeline Insight 2025: Advancing Biologic Frontiers to Transform Chronic Skin Disease Management | DelveInsight

DelveInsight's "Moderate to Severe Plaque Psoriasis - Pipeline Insight, 2025" report provides a comprehensive analysis of the drug development landscape for this chronic, immune-mediated skin condition, spotlighting over 30 pipeline therapies in clinical evaluation. The report focuses on next-generation biologics and oral agents targeting key immunological pathways such as IL-17, IL-23, TNF-α, and JAK-STAT signaling.

The treatment paradigm for moderate to severe plaque psoriasis is undergoing a rapid shift, with newer agents aiming to provide faster skin clearance, longer durability of response, and improved safety profiles. Promising candidates include bimekizumab, mirikizumab, JNJ-77242113, and deucravacitinib, many of which have shown high Psoriasis Area and Severity Index (PASI) scores and durable remission in pivotal trials.

Biopharma players such as UCB, Eli Lilly, AbbVie, Johnson & Johnson, and Bristol Myers Squibb are at the forefront of innovation, with novel therapies offering unique mechanisms of action, including TYK2 inhibition and dual cytokine blockade. These therapies are also being evaluated for co-morbid conditions like psoriatic arthritis and inflammatory bowel disease, enhancing their market potential.

The report also highlights key clinical milestones, regulatory updates, evolving biomarker strategies, and potential first-in-class therapies reshaping the competitive landscape. With a focus on patient-centric outcomes and personalized approaches, the psoriasis pipeline holds the promise of long-term disease control beyond symptom management.

Interested in learning more about the current treatment landscape and the key drivers shaping the moderate to severe plaque psoriasis pipeline? Click here: https://www.delveinsight.com/report-store/moderate-to-severe-plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Moderate to Severe Plaque Psoriasis Pipeline Report
• DelveInsight's moderate to severe plaque psoriasis pipeline analysis depicts a strong space with 30+ active players working to develop 30+ pipeline drugs for moderate to severe plaque psoriasis treatment.
• The leading moderate to severe plaque psoriasis companies include Bristol-Myers Squibb, Akeso Biopharma, Jiangsu Hengrui Medicine, Nimbus Therapeutics, Sun Pharmaceutical Industries Limited, Suzhou Zelgen Biopharmaceuticals, GC Cell Corporation, Bioeq GmbH, Dong-A ST Co., Ltd., Can-Fite Biopharma, Bio-Thera Solutions, AbbVie, Sinocelltech, Janssen Research and Development, Innovent Biologics, Aurigene Discovery, Affibody, GlaxoSmithKline, Abcentra, and others are evaluating their lead assets to improve the moderate to severe plaque psoriasis treatment landscape.
• Key moderate to severe plaque psoriasis pipeline therapies in various stages of development include BMS-986165, SHR 1314, Ebdarokimab, NDI 034858, SCD-044, Jaktinib, CT 303, FYB202, DMB-3115, CF101, BAT2206, ABP 654, SCT630, JTE-451, JNJ-77242113, IBI112, and others.
• In June 2025, the National Psoriasis Foundation (NPF) awarded its Seal of Recognition to Arcutis Biotherapeutics' ZORYVE (roflumilast) cream 0.3% and topical foam 0.3%, both FDA-approved for plaque psoriasis. ZORYVE is the first FDA-approved treatment to receive this Seal, recognizing products that are non-irritating and safe for people with psoriasis.
• In May 2025, Arcutis Biotherapeutics (Nasdaq: ARQT) announced FDA approval of the supplemental NDA for ZORYVE (roflumilast) topical foam 0.3%, now approved to treat scalp and body plaque psoriasis in patients aged 12 and older.
• In May 2025, Fresenius Kabi and Formycon AG announced that the FDA designated OTULFI (ustekinumab-aauz) as an interchangeable biosimilar to STELARA (ustekinumab) for treating plaque psoriasis.
• In May 2025, Teva Pharmaceuticals and Alvotech announced that the FDA approved SELARSDI (ustekinumab-aekn) injection as interchangeable with the reference biologic STELARA (ustekinumab). Starting April 30, 2025, SELARSDI is available in all presentations matching the reference product for the treatment of adults and pediatric patients with psoriatic arthritis, plaque psoriasis, Crohn's disease, and ulcerative colitis.
• In March 2025, Biocon Biologics Ltd. announced successful results from a pivotal Phase 3, randomized, double-blind, multicenter study comparing YESINTEK (biosimilar to Ustekinumab) with the reference product Stelara (Ustekinumab) in adults with moderate to severe chronic plaque psoriasis (PsO).

Request a sample and discover the recent breakthroughs happening in the moderate to severe plaque psoriasis pipeline landscape at https://www.delveinsight.com/report-store/moderate-to-severe-plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Moderate to Severe Plaque Psoriasis Overview
Moderate to severe plaque psoriasis is a chronic autoimmune skin condition characterized by the rapid buildup of skin cells, leading to thick, red, scaly patches called plaques. These plaques often cause itching, discomfort, and can significantly impact a patient's quality of life. The disease typically affects large areas of the body, such as the scalp, elbows, knees, and trunk.

Treatment for moderate to severe plaque psoriasis usually involves systemic therapies, including biologics that target specific immune pathways, oral medications, and phototherapy. Advances in understanding the immune mechanisms behind psoriasis have led to more effective and targeted treatments, improving outcomes and reducing symptoms for many patients.

Find out more about moderate to severe plaque psoriasis medication at https://www.delveinsight.com/report-store/moderate-to-severe-plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Moderate to Severe Plaque Psoriasis Treatment Analysis: Drug Profile
BMS-986165: Bristol Myers Squibb
Deucravacitinib (BMS-986165) is an oral, first-in-class selective tyrosine kinase 2 (TYK2) inhibitor developed by Bristol Myers Squibb. It works by selectively inhibiting TYK2-mediated signaling of key cytokines such as interleukin (IL)-12, IL-23, and type 1 interferons-critical drivers of inflammation in psoriasis and other immune-mediated conditions. Recognized with the 2019 Thomas Alva Edison Patent Award, deucravacitinib represents a novel therapeutic approach and is currently being evaluated in clinical trials across a range of autoimmune diseases, including psoriasis, psoriatic arthritis, lupus, and inflammatory bowel disease.

AK111: Akeso Biopharma
AK111 is an investigational IL-17A monoclonal antibody being developed by Akeso Biopharma for the treatment of autoimmune disorders. Designed to block the IL-17 pathway by targeting both IL-17A and its receptor (IL-17RA), AK111 aims to suppress inflammatory responses in diseases such as moderate to severe plaque psoriasis, ankylosing spondylitis, and axial spondyloarthritis. The drug is currently in Phase II clinical development for moderate to severe plaque psoriasis.

Learn more about the novel and emerging moderate to severe plaque psoriasis pipeline therapies at https://www.delveinsight.com/report-store/moderate-to-severe-plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Moderate to Severe Plaque Psoriasis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Moderate to Severe Plaque Psoriasis Pipeline Report
• Coverage: Global
• Key Moderate to Severe Plaque Psoriasis Companies: Bristol-Myers Squibb, Akeso Biopharma, Jiangsu Hengrui Medicine, Nimbus Therapeutics, Sun Pharmaceutical Industries Limited, Suzhou Zelgen Biopharmaceuticals, GC Cell Corporation, Bioeq GmbH, Dong-A ST Co., Ltd., Can-Fite Biopharma, Bio-Thera Solutions, AbbVie, Sinocelltech, Janssen Research and Development, Innovent Biologics, Aurigene Discovery, Affibody, GlaxoSmithKline, Abcentra, and others.
• Key Moderate to Severe Plaque Psoriasis Pipeline Therapies: BMS-986165, SHR 1314, Ebdarokimab, NDI 034858, SCD-044, Jaktinib, CT 303, FYB202, DMB-3115, CF101, BAT2206, ABP 654, SCT630, JTE-451, JNJ-77242113, IBI112, and others.

To dive deep into rich insights for drugs used for moderate to severe plaque psoriasis treatment, visit: https://www.delveinsight.com/report-store/moderate-to-severe-plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Moderate to Severe Plaque Psoriasis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Moderate to Severe Plaque Psoriasis Pipeline Therapeutics
6. Moderate to Severe Plaque Psoriasis Pipeline: Late-Stage Products (Phase III)
7. Moderate to Severe Plaque Psoriasis Pipeline: Mid-Stage Products (Phase II)
8. Moderate to Severe Plaque Psoriasis Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.